Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.24 HKD
−232.70 M HKD
241.74 M HKD
473.71 M
About ALPHAMAB ONCOLOGY
Sector
Industry
CEO
Ting Xu
Website
Headquarters
Suzhou
Founded
2008
FIGI
BBG00QX1PZW3
Alphamab Oncology is an investment holding company. It engages in the research and development, manufacturing and commercialization of biologics of oncology through its subsidiaries. The company was founded by Xu Ting in Novemeber 2008 and is headquartered in Suzhou, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 9966 is 3.44 HKD — it has increased by 1.18% in the past 24 hours. Watch ALPHAMAB ONCOLOGY stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange ALPHAMAB ONCOLOGY stocks are traded under the ticker 9966.
9966 stock has risen by 0.88% compared to the previous week, the month change is a −25.86% fall, over the last year ALPHAMAB ONCOLOGY has showed a −46.25% decrease.
We've gathered analysts' opinions on ALPHAMAB ONCOLOGY future price: according to them, 9966 price has a max estimate of 5.00 HKD and a min estimate of 5.00 HKD. Watch 9966 chart and read a more detailed ALPHAMAB ONCOLOGY stock forecast: see what analysts think of ALPHAMAB ONCOLOGY and suggest that you do with its stocks.
9966 reached its all-time high on Jul 14, 2021 with the price of 28.70 HKD, and its all-time low was 2.00 HKD and was reached on May 29, 2024. View more price dynamics on 9966 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
9966 stock is 2.65% volatile and has beta coefficient of 2.17. Track ALPHAMAB ONCOLOGY stock price on the chart and check out the list of the most volatile stocks — is ALPHAMAB ONCOLOGY there?
Yes, you can track ALPHAMAB ONCOLOGY financials in yearly and quarterly reports right on TradingView.
ALPHAMAB ONCOLOGY is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
9966 net income for the last half-year is −48.65 M HKD, while the previous report showed −184.45 M HKD of net income which accounts for 73.62% change. Track more ALPHAMAB ONCOLOGY financial stats to get the full picture.
No, 9966 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 435.00 employees. See our rating of the largest employees — is ALPHAMAB ONCOLOGY on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALPHAMAB ONCOLOGY EBITDA is −228.17 M HKD, and current EBITDA margin is −116.20%. See more stats in ALPHAMAB ONCOLOGY financial statements.
Like other stocks, 9966 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALPHAMAB ONCOLOGY stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALPHAMAB ONCOLOGY technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALPHAMAB ONCOLOGY stock shows the sell signal. See more of ALPHAMAB ONCOLOGY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.